Mar. 20 at 3:39 PM
$BIXT -- Let's Talk About What This PR Isn't Saying
The science is real. ProLectin-M showing 90% viral clearance at Day 5 is interesting data and the Phase 3 roadmap is credible. Nobody is disputing the technology.
But the timing deserves scrutiny.
OS went from 89M to 113M shares and has been sitting at 113M for six weeks. That dilution happened in January. Restricted stock sales at
$0.05 with 100% warrant coverage at
$0.12 started in November 2025. Why are we reading about a closed deal today in March?
That's not timely disclosure.
And here's the uncomfortable part: the CEO got 30 million shares --
$1.5M equivalent -- as compensation for raising this round on a stock trading at
$0.037.
If they raise another
$1M, does he get another
$1.5M stock award?
Great tech. Terrible stewardship. Know the difference before you size your position.
$BIXT #OTC #Biotech
